WO2000074684A1 - Formulations pharmaceutiques pour traiter des femmes en periode de postmenopause et de perimenopause, et leur utilisation - Google Patents

Formulations pharmaceutiques pour traiter des femmes en periode de postmenopause et de perimenopause, et leur utilisation Download PDF

Info

Publication number
WO2000074684A1
WO2000074684A1 PCT/US2000/040061 US0040061W WO0074684A1 WO 2000074684 A1 WO2000074684 A1 WO 2000074684A1 US 0040061 W US0040061 W US 0040061W WO 0074684 A1 WO0074684 A1 WO 0074684A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical formulation
woman
derivatives
progestin
postmenopausal
Prior art date
Application number
PCT/US2000/040061
Other languages
English (en)
Inventor
Kathryn A. Martin
William F. Crowley, Jr.
Original Assignee
The General Hospital Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The General Hospital Corporation filed Critical The General Hospital Corporation
Priority to AU51812/00A priority Critical patent/AU5181200A/en
Priority to EP00936507A priority patent/EP1187618A1/fr
Priority to JP2001501220A priority patent/JP2003501390A/ja
Publication of WO2000074684A1 publication Critical patent/WO2000074684A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

L'invention porte sur des formulations pharmaceutiques contenant diverses combinaisons d'un oestrogène, d'une progestérone, d'un androgène, d'un modulateur de récepteur d'oestrogène sélectif, d'un modulateur de récepteur d'androgène sélectif, ces formulations étant destinées à être utilisées pour traiter les femmes en période de postménopause ou de périménopause. L'invention porte également sur des procédés de traitement au moyen des formulations pharmaceutiques précitées.
PCT/US2000/040061 1999-06-04 2000-06-02 Formulations pharmaceutiques pour traiter des femmes en periode de postmenopause et de perimenopause, et leur utilisation WO2000074684A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU51812/00A AU5181200A (en) 1999-06-04 2000-06-02 Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use
EP00936507A EP1187618A1 (fr) 1999-06-04 2000-06-02 Formulations pharmaceutiques pour traiter des femmes en periode de postmenopause et de perimenopause, et leur utilisation
JP2001501220A JP2003501390A (ja) 1999-06-04 2000-06-02 閉経後及び閉経期の女性を治療するための薬学的製剤、及びそれらの利用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13744099P 1999-06-04 1999-06-04
US60/137,440 1999-06-04

Publications (1)

Publication Number Publication Date
WO2000074684A1 true WO2000074684A1 (fr) 2000-12-14

Family

ID=22477447

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/040061 WO2000074684A1 (fr) 1999-06-04 2000-06-02 Formulations pharmaceutiques pour traiter des femmes en periode de postmenopause et de perimenopause, et leur utilisation

Country Status (4)

Country Link
EP (1) EP1187618A1 (fr)
JP (1) JP2003501390A (fr)
AU (1) AU5181200A (fr)
WO (1) WO2000074684A1 (fr)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092102A2 (fr) * 2001-05-16 2002-11-21 Endeavor Pharmaceuticals Traitement d'etats lies a un deficit en hormones par administration de progestatifs
WO2003063859A1 (fr) * 2002-01-14 2003-08-07 Nordic Bioscience A/S Suppression de la degradation du cartilage a l'aide du recepteur des oestrogenes
WO2003082299A1 (fr) * 2002-04-03 2003-10-09 Jencap Research Ltd. Hormonotherapie substitutive amelioree
WO2004022065A1 (fr) * 2002-09-05 2004-03-18 Pantarhei Bioscience B.V. Application pharmaceutique d'analogues de testosterone a substitution 15 ou 16
JP2004515531A (ja) * 2000-12-15 2004-05-27 ノボ ノルディスク アクティーゼルスカブ 萎縮性膣炎の治療のためのエストロゲンを含有する組成物の製造におけるエストロゲンの使用
EP1494679A1 (fr) * 2002-04-03 2005-01-12 Barr Laboratories, Inc. Therapie oestrogenique a diminution graduelle
EP1522306A1 (fr) * 2003-10-08 2005-04-13 Liconsa, Liberacion Controlada de Sustancias Activas, S.A. Un produit pharmaceutique pour le traitement hormonal substitutif contenant la tibolone ou un de ses dérivés et l'estradiol ou un de ses dérivés
JP2005511725A (ja) * 2001-12-13 2005-04-28 バイタル ヘルス サイエンシズ プロプライアタリー リミティド 化合物の経皮輸送
EP1583536A2 (fr) * 2003-01-17 2005-10-12 Erik P. Castle Méthode de traitement du cancer de la prostate et composition pour son traitement
US7030157B2 (en) 2001-07-31 2006-04-18 Pfizer Inc. Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
AU2002243411B2 (en) * 2000-12-22 2007-02-08 Barr Laboratories, Inc. Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy
EP1862165A2 (fr) * 2001-11-29 2007-12-05 GTX, Inc. Prévention et traitement des bouffées de chaleur à carence androgène
WO2007144151A1 (fr) * 2006-06-13 2007-12-21 Bayer Schering Pharma Aktiengesellschaft Schéma posologique décroissant d'œstrogène pour des femmes recevant une thérapie par œstrogène
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
US8841342B2 (en) 2002-08-09 2014-09-23 Vital Health Sciences Pty. Ltd. Carrier
US9125816B2 (en) 2000-08-30 2015-09-08 Besins Healthcare Inc. Pharmaceutical composition and method for treating hypogonadism
US9168216B2 (en) 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
WO2016028903A1 (fr) * 2014-08-20 2016-02-25 Professional Compounding Centers Of America Compositions pharmaceutiques pour l'administration par voie transmuqueuse orale comprenant de la testostérone et un c-serm
US9314527B2 (en) 2010-03-30 2016-04-19 Phosphagenics Limited Transdermal delivery patch
US9561243B2 (en) 2011-03-15 2017-02-07 Phosphagenics Limited Composition comprising non-neutralised tocol phosphate and a vitamin A compound
US10071030B2 (en) 2010-02-05 2018-09-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
WO2020010205A1 (fr) * 2018-07-05 2020-01-09 Celista Pharmaceuticals Llc Pulvérisateur transdermique de testostérone et d'estradiol
EP3613418A1 (fr) * 2014-01-17 2020-02-26 Ligand Pharmaceuticals, Inc. Procédés et compositions de modulation des niveaux d'hormones
WO2020247653A1 (fr) * 2019-06-06 2020-12-10 Evestra, Inc. Contraception hormonale au moyen d'un anneau vaginal qui libère l'estriol et la trimégestone
US10973761B2 (en) 2015-12-09 2021-04-13 Phosphagenics Limited Pharmaceutical formulation
US11753435B2 (en) 2016-12-21 2023-09-12 Avecho Biotechnology Limited Process

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005298450A (ja) * 2004-04-15 2005-10-27 Taisho Pharmaceut Co Ltd 更年期症候群の予防又は治療剤組成物
UY33103A (es) * 2009-12-15 2011-07-29 Techsphere S A De C V Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340585A (en) * 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5770226A (en) * 1996-07-10 1998-06-23 Wake Forest University Combined pharmaceutical estrogen-androgen-progestin oral contraceptive
US5846960A (en) * 1991-06-28 1998-12-08 Endorecherche, Inc. Methods for preventing and treating osteoporosis with low dose non-masculinizing androgenic compounds
US5955455A (en) * 1993-01-19 1999-09-21 Endorecherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340585A (en) * 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5846960A (en) * 1991-06-28 1998-12-08 Endorecherche, Inc. Methods for preventing and treating osteoporosis with low dose non-masculinizing androgenic compounds
US5955455A (en) * 1993-01-19 1999-09-21 Endorecherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
US5770226A (en) * 1996-07-10 1998-06-23 Wake Forest University Combined pharmaceutical estrogen-androgen-progestin oral contraceptive

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9132089B2 (en) 2000-08-30 2015-09-15 Besins Healthcare Inc. Pharmaceutical composition and method for treating hypogonadism
US9125816B2 (en) 2000-08-30 2015-09-08 Besins Healthcare Inc. Pharmaceutical composition and method for treating hypogonadism
JP4851057B2 (ja) * 2000-12-15 2012-01-11 ノボ・ノルディスク・フェムケア・アーゲー 萎縮性膣炎の治療のためのエストロゲンを含有する組成物の製造におけるエストロゲンの使用
JP2004515531A (ja) * 2000-12-15 2004-05-27 ノボ ノルディスク アクティーゼルスカブ 萎縮性膣炎の治療のためのエストロゲンを含有する組成物の製造におけるエストロゲンの使用
AU2002243411B2 (en) * 2000-12-22 2007-02-08 Barr Laboratories, Inc. Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy
WO2002092102A2 (fr) * 2001-05-16 2002-11-21 Endeavor Pharmaceuticals Traitement d'etats lies a un deficit en hormones par administration de progestatifs
WO2002092102A3 (fr) * 2001-05-16 2003-03-20 Endeavor Pharmaceuticals Traitement d'etats lies a un deficit en hormones par administration de progestatifs
US8076319B2 (en) 2001-05-16 2011-12-13 Barr Laboratories, Inc. Treatment of conditions relating to hormone deficiencies by administration of progestins
US7683047B2 (en) 2001-05-16 2010-03-23 Barr Laboratories, Inc. Treatment of conditions relating to hormone deficiencies by administration of progestins
US7427609B2 (en) 2001-05-16 2008-09-23 Barr Laboratories, Inc. Treatment of conditions relating to hormone deficiencies by administration of progestins
US7030157B2 (en) 2001-07-31 2006-04-18 Pfizer Inc. Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
EP1862165A2 (fr) * 2001-11-29 2007-12-05 GTX, Inc. Prévention et traitement des bouffées de chaleur à carence androgène
EP1862165A3 (fr) * 2001-11-29 2008-06-25 GTX, Inc. Prévention et traitement des bouffées de chaleur à carence androgène
JP2005511725A (ja) * 2001-12-13 2005-04-28 バイタル ヘルス サイエンシズ プロプライアタリー リミティド 化合物の経皮輸送
WO2003063859A1 (fr) * 2002-01-14 2003-08-07 Nordic Bioscience A/S Suppression de la degradation du cartilage a l'aide du recepteur des oestrogenes
WO2003082299A1 (fr) * 2002-04-03 2003-10-09 Jencap Research Ltd. Hormonotherapie substitutive amelioree
EP1494679A4 (fr) * 2002-04-03 2009-10-28 Barr Lab Inc Therapie oestrogenique a diminution graduelle
EP1494679A1 (fr) * 2002-04-03 2005-01-12 Barr Laboratories, Inc. Therapie oestrogenique a diminution graduelle
US8841342B2 (en) 2002-08-09 2014-09-23 Vital Health Sciences Pty. Ltd. Carrier
WO2004022065A1 (fr) * 2002-09-05 2004-03-18 Pantarhei Bioscience B.V. Application pharmaceutique d'analogues de testosterone a substitution 15 ou 16
US7943602B2 (en) 2002-09-05 2011-05-17 Pantarhei Bioscience B.V. Pharmaceutical application of 15- or 16-substituted testosterone analogues
EP1583536A4 (fr) * 2003-01-17 2009-07-15 Erik P Castle Méthode de traitement du cancer de la prostate et composition pour son traitement
EP1583536A2 (fr) * 2003-01-17 2005-10-12 Erik P. Castle Méthode de traitement du cancer de la prostate et composition pour son traitement
EP1522306A1 (fr) * 2003-10-08 2005-04-13 Liconsa, Liberacion Controlada de Sustancias Activas, S.A. Un produit pharmaceutique pour le traitement hormonal substitutif contenant la tibolone ou un de ses dérivés et l'estradiol ou un de ses dérivés
WO2005037288A1 (fr) * 2003-10-08 2005-04-28 Liconsa, Liberación Controlada de Sustancias Activas, S.A. Produit pharmaceutique pour traitement hormonal substitutif comprenant de la tibolone ou un derive de celle-ci et de l'estradiol ou un derive de celui-ci
US9168216B2 (en) 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
WO2007144151A1 (fr) * 2006-06-13 2007-12-21 Bayer Schering Pharma Aktiengesellschaft Schéma posologique décroissant d'œstrogène pour des femmes recevant une thérapie par œstrogène
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
US10071030B2 (en) 2010-02-05 2018-09-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
US9314527B2 (en) 2010-03-30 2016-04-19 Phosphagenics Limited Transdermal delivery patch
US9427400B2 (en) 2010-10-19 2016-08-30 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
US9561243B2 (en) 2011-03-15 2017-02-07 Phosphagenics Limited Composition comprising non-neutralised tocol phosphate and a vitamin A compound
US10188670B2 (en) 2011-03-15 2019-01-29 Phosphagenics Limited Composition
US11793669B2 (en) 2013-11-14 2023-10-24 The Population Council, Inc. Combination therapy intravaginal rings
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
US11259956B2 (en) 2013-11-14 2022-03-01 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
US10874638B2 (en) 2014-01-17 2020-12-29 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
EP3613418A1 (fr) * 2014-01-17 2020-02-26 Ligand Pharmaceuticals, Inc. Procédés et compositions de modulation des niveaux d'hormones
WO2016028903A1 (fr) * 2014-08-20 2016-02-25 Professional Compounding Centers Of America Compositions pharmaceutiques pour l'administration par voie transmuqueuse orale comprenant de la testostérone et un c-serm
US9452174B2 (en) 2014-08-20 2016-09-27 Professional Compounding Centers Of America Oral transmucosal pharmaceutical compositions including testosterone and a C-SERM
US10973761B2 (en) 2015-12-09 2021-04-13 Phosphagenics Limited Pharmaceutical formulation
US11753435B2 (en) 2016-12-21 2023-09-12 Avecho Biotechnology Limited Process
WO2020010205A1 (fr) * 2018-07-05 2020-01-09 Celista Pharmaceuticals Llc Pulvérisateur transdermique de testostérone et d'estradiol
WO2020247653A1 (fr) * 2019-06-06 2020-12-10 Evestra, Inc. Contraception hormonale au moyen d'un anneau vaginal qui libère l'estriol et la trimégestone

Also Published As

Publication number Publication date
EP1187618A1 (fr) 2002-03-20
AU5181200A (en) 2000-12-28
JP2003501390A (ja) 2003-01-14

Similar Documents

Publication Publication Date Title
WO2000074684A1 (fr) Formulations pharmaceutiques pour traiter des femmes en periode de postmenopause et de perimenopause, et leur utilisation
Kupperman et al. Contemporary therapy of the menopausal syndrome
Kuhl Pharmacology of estrogens and progestogens: influence of different routes of administration
US5585370A (en) Hormone preparation and method
JP5184727B2 (ja) 女性への非経口アンドロゲンステロイドの投与
EP0559240B1 (fr) Packages contraceptives contenant de l'estrogen et du progestin
US7320970B2 (en) Low dose estrogen interrupted hormone replacement therapy
US8338400B2 (en) Methods and apparatus for transdermal or transmucosal application of testosterone
US4310523A (en) Combined antiestrogens and antigonadotropically effective antiandrogens for the prophylaxis and therapy of hyperplasia of the prostate
RU2340345C2 (ru) Схема восполнения эстрогена
US20030022877A1 (en) Method of increasing testosterone and related steroid concentrations in women
DE602004002591T2 (de) Verwendung von zusammensetzungen enthaltend ein oestrogen zur behandlung und verhinderung von muskelskelettschmerzen
US5256421A (en) Hormone preparation and method
HU221169B1 (en) Use of estrogen and antiprogestin for producing pharmaceutical compositions useful in hormon replacement therapy and kit containing the same
JP2005514345A (ja) 更年期以降の女性生殖機能障害の治療のための組成物
US9034854B2 (en) Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
US20060014728A1 (en) Hormone replacement therapy
JP2003511399A (ja) 女性避妊薬の成分としてのメソプロゲスチン（プロゲステロン受容体モジュレーター）
EP0850647B1 (fr) Application de composés stéroides substitués en ll pour la fabrication de médicaments ayant une activité estrogène dissociée
US20210386757A1 (en) Methods of Treating Menopausal Symptoms Using Low Dose Progesterone
IE84449B1 (en) Contraceptive packages containing oestrogen and progestin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 501220

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000936507

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000936507

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000936507

Country of ref document: EP